Quantum Surgical Partners with the Taiwanese Distributor Unison Healthcare Group 

Quantum Surgical extends its presence in Taiwan in partnership with Unison Healthcare Group. Quantum Surgical’s robotic platform Epione is already used in fifteen cancer centers in Europe and in the USA. 

Quantum Surgical develops the Epione^® robotic platform. It assists physicians in performing percutaneous tumor ablations, where one or more needles are inserted through the skin to destroy the tumor. This minimally invasive treatment provides patients with a safe and effective alternative to surgery.

Epione can treat tumors located in the abdomen (liver, kidney, pancreas) in the lungs, and is currently used to treat tumors in the liver in about fifteen cancer centers worldwide. Over 800 patients have already been treated worldwide.

Quantum Surgical now partners with UHG to strategically expand activities in Taiwan, according to the latest statistics, the number of newly diagnosed cancer cases in Taiwan in 2022 is estimated to be 132,293, an increase of 8,531 cases compared to 2021.

Bertin Nahum, CEO and co-founder of Quantum Surgical explains “We are thrilled to expand our activities in Taiwan with Unison Healthcare Group, as our mission is to improve early-stage cancer treatment worldwide and ensure that as many cancer patients as possible can benefit from our minimally invasive technology”.

Daniel Shih, Chairman and President of Unison Healthcare Group (UHG) declares ”The partnership between UHG and Quantum Surgical’s founders began with their former venture Medtech and the ROSA surgical robot. The Group is honored to work with Quantum Surgical again to promote the minimally invasive surgical robotic system for cancer treatment. We hope that the new generation of minimally invasive cancer surgical robots will elevate the quality of Taiwan’s cancer treatment industry”.

Source: Quantum Surgical